Peru suspends China's Sinopharm COVID-19 vaccine trial

▴ Peru suspends China's Sinopharm COVID-19 vaccine trial
Peru suspended trials for China's Sinopharm COVID-19 vaccine due to a "serious adverse event" that occurred with one of the volunteers for the study, the Peruvian government said in a statement on Saturday.

German Malaga, chief researcher at the local Cayetano Heredia University, which is involved with the study, said one volunteer had experienced decreased strength in his legs, among other symptoms.

Malaga also said he was hopeful the suspension would lifted and the trial resume in a short period of time.

The health ministry said the event is "under investigation to determine if it is related to the vaccine or if there is another explanation."

Sinopharm Group Co Ltd, which is conducting its trials in Peru with some 12,000 volunteers, was about to complete the first stage of the trials in the next few days. Some 36,544 people have died so far in Peru from the coronavirus pandemic.

Back at home India steadily following the trend set over the past few weeks. Country's active caseload has fallen to 3.62% of the total active cases.

India has reported more daily recoveries than the daily new cases during the past 48 hours. The trend of more daily recoveries than the daily cases has led to a continuous contraction of India’s Active Caseload which presently stands at 3,56,546 yesterday.

While 30,254 persons in were found to be COVID positive in the country in the past 24 hours, 33,136 new recoveries were registered during the same period. This has led to a net decline of 3,273 cases from the total Active Caseload in the last 24 hours.

Tags : #Peru #LatestCOVIDNews14thDec #LatestCOVIDVaccineNews14thDec #Sinopharm #China #India #ActiveCaseload #IndiaFightsCorona #Unite2FightCorona

About the Author


Team Medicircle

Related Stories

Loading Please wait...

-Advertisements-




Trending Now

The Role of Genetic Profiles in Alzheimer’s Therapy: APOE4 and Treatment ResponsesMay 08, 2024
Assessing Covishield Safety: Indian Research Offers Reassurance Amidst Rare Side Effect DiscussionsMay 08, 2024
Quadria Capital Invests $102 Million in NephroPlus to Boost Dialysis Services Across AsiaMay 08, 2024
When Your Body Makes Beer: Exploring the Curious Case of Auto-Brewery SyndromeMay 07, 2024
Hair Today, Gone Tomorrow: Why Guys Go Bald Before Marriage May 07, 2024
Menopausal Transitions and Mental Health: UCL Study Highlights Increased Depression RiskMay 07, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Vasavi Club of Buddhapurnima organised #GoVote, a vote awareness driveMay 06, 2024
Harnessing AI for Early Alzheimer's Disease Diagnosis: IIT Indore's BreakthroughMay 06, 2024
Aurobindo Pharma's Bhiwadi Facility Under FDA Scrutiny: Understanding the ObservationsMay 06, 2024
Exploring the Role of Mediator Protein Complex in Cell Division: Implications for Disease ManagementMay 06, 2024
Akshay Tritiya Parna Mahotsav is to be held in the cityMay 04, 2024
Bharti Singh's Battle with Gallstones: Symptoms, Precautions, and Natural RemediesMay 04, 2024
Empowering Women's Health: New Mammogram GuidelinesMay 04, 2024
Rising Temperatures, Rising Risks: Addressing the Challenges of Heat StressMay 04, 2024
Gynoveda, India's First Ayurveda Fertility Company, Expands Reach with New Clinic in Pune, Set to Open 100 Clinics Across India by 2027May 03, 2024
Aptus Value Housing Finance India Limited, a leading Housing Finance Company has declared its financial results for the year ended March 31, 2024. FY 24 ResultsMay 03, 2024
TIPS FOR PREGNANCY CARE DURING SUMMERMay 03, 2024
The deadly intersection: TB and tobacco smoking co-epidemics in Indonesia Dr TARA SINGH BAM – CNSMay 03, 2024
Mintoak Expands Global Footprint with Strategic Leadership AppointmentsMay 03, 2024